Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

SCRAS claims NOS inhibitors

Oct. 25, 1996

Glaxo Wellcome claims NMDA antagonists

Oct. 25, 1996

Twenty-four drugs in development for Alzheimer's disease in U.S.

Oct. 25, 1996

Two Alzheimer's drugs in phase III in Japan

Oct. 25, 1996

Spotlight on ALS research

Oct. 25, 1996

Cephalosporin tested in Italian patients with ALS

Oct. 25, 1996

Talipexole now available in Japan

Oct. 25, 1996

Neuroprotective calpain inhibitors from Warner-Lambert

Oct. 18, 1996

Huperzine A analogues claimed for treatment of AD

Oct. 18, 1996

Lilly's benzimidazole compounds for beta-amyloid peptide-associated disorders

Oct. 18, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...